Proteomics International secures US patent grant for endometriosis innovative diagnostic test
United States Patent and Trademark Office (USPTO) has granted a new patent for the PromarkerEndo proprietary blood test for the diagnosis of endometriosis
Major milestone with patent granted in the world’s largest healthcare market
The patent supports commercialisation efforts and underpins the commercialisation pathway, enabling future partnerships and licensing opportunities.
Published clinical data has demonstrated the patented blood test has high accuracy for diagnosing endometriosis, including in the early stages of the disease
Patent protection for the PromarkerEndo technology has now advanced in major jurisdictions including Japan and the United States
Global need - endometriosis affects one in nine women and currently diagnosis typically takes an average of 7 years
View ASX Announcement: here